Nuts to That
Severe, even life-threatening peanut allergies afflict 3 million people in the United States alone. The only protection now available is to avoid peanuts and their derivatives. While it’s easy to eschew peanut butter sandwiches, who’s to know if the chips at the office party were fried in peanut oil? Houston-based Tanox has begun human testing of a once-a-month injection to protect the peanut-averse from accidental exposure. The drug, Hu-901, is an antibody that blocks the immune reaction responsible for swelling and itching. People taking it probably won’t be able to eat nuts daily, but they should have more time to get help if they do eat those chips.
If Hu-901 is effective in preventing peanut allergies, Tanox may investigate its use against other food allergies. The company hopes a similar antibody to treat seasonal allergies and asthma will get regulatory approval by mid-2001.
Keep Reading
Most Popular
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.